58.09

0.07% -0.04

After Hours: 52.29 -5.80 -9.98%

Ionis Pharmaceuticals Inc (IONS)

Overview News Price History Option Chain Financials Discussions Forecast

Ionis Pharmaceuticals Inc stock is traded at $58.09, with a volume of 2.31M. It is down -0.07% in the last 24 hours and up +5.48% over the past month. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Previous Close:

$58.13

Open:

$58.36

24h Volume:

2.31M

Relative Volume:

0.81

Market Cap:

$9.65B

Revenue:

$1.06B

Net Income/Loss:

$-326.58M

P/E Ratio:

-27.63

EPS:

-2.1022

Net Cash Flow:

$-977.73M

1W Performance:

-4.85%

1M Performance:

+5.48%

6M Performance:

-26.88%

1Y Performance:

-2.12%

1-Day Range:

$57.78

$58.96

1-Week Range:

$57.47

$61.77

52-Week Range:

$50.01

$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name

Ionis Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(760) 931-9200

Address

2855 GAZELLE COURT, CARLSBAD, CA

Employee

1,402

Twitter

@ionispharma

Next Earnings Date

2026-07-29

Latest SEC Filings

IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IONS Ionis Pharmaceuticals Inc	58.09	9.76B	1.06B	-326.58M	-977.73M	-2.1022
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Initiated	Canaccord Genuity	Buy
Apr-10-26	Resumed	Raymond James	Outperform
Jan-28-26	Resumed	Barclays	Overweight
Oct-08-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-26-25	Upgrade	Goldman	Sell → Neutral
Sep-03-25	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-31-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-01-25	Upgrade	Barclays	Equal Weight → Overweight
Apr-07-25	Initiated	H.C. Wainwright	Buy
Mar-31-25	Initiated	Redburn Atlantic	Neutral
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-16-24	Resumed	Jefferies	Buy
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral
Sep-29-23	Initiated	Raymond James	Strong Buy
Jul-31-23	Upgrade	Citigroup	Neutral → Buy
Jun-07-23	Resumed	Piper Sandler	Overweight
May-04-23	Upgrade	Citigroup	Sell → Neutral
Mar-21-23	Initiated	Bernstein	Underperform
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-09-22	Resumed	Morgan Stanley	Overweight
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-31-22	Resumed	Piper Sandler	Overweight
Mar-01-22	Initiated	Citigroup	Sell
Mar-01-22	Initiated	Guggenheim	Buy
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform
Dec-14-21	Upgrade	William Blair	Mkt Perform → Outperform
May-07-21	Upgrade	UBS	Sell → Neutral
Mar-01-21	Upgrade	Barclays	Underweight → Equal Weight
Dec-16-20	Initiated	UBS	Sell
Dec-15-20	Upgrade	Cowen	Market Perform → Outperform
Sep-14-20	Resumed	JP Morgan	Neutral
Sep-02-20	Initiated	The Benchmark Company	Hold
Jun-01-20	Resumed	Oppenheimer	Outperform
May-13-20	Initiated	RBC Capital Mkts	Outperform
Mar-05-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
Nov-07-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Sep-10-19	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-08-18	Reiterated	Stifel	Hold
Aug-07-18	Reiterated	Stifel	Hold
May-08-18	Downgrade	Evercore ISI	Outperform → In-line
Oct-06-17	Resumed	Goldman	Sell
Aug-17-17	Initiated	Evercore ISI	Outperform
Aug-09-17	Reiterated	Stifel	Hold
Mar-10-17	Downgrade	Goldman	Neutral → Sell
Dec-28-16	Reiterated	BMO Capital Markets	Outperform
Dec-27-16	Reiterated	Leerink Partners	Mkt Perform

View All

Ionis Pharmaceuticals Inc Stock (IONS) Latest News

Aug 20, 2026

Ionis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:IONS) - MarketBeat

Aug 20, 2026

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - BioSpace

Aug 20, 2026

IONS Looks 26.4% Overvalued on GF Value™ - GuruFocus

Aug 20, 2026

Why Is Ionis Pharmaceuticals (IONS) Pushing RG-6299 Into A Pivotal Phase III Trial? - Sahm

Aug 20, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Hold at BMO Capital Markets - MarketBeat

Aug 20, 2026

Eagle Health Investments LP Acquires New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 20, 2026

DCF Advisers LLC Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 20, 2026

Edmond DE Rothschild Holding S.A. Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 20, 2026

Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 20, 2026

Aug 19, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Earns Market Perform Rating from Analysts at BMO Capital Markets - MarketBeat

Aug 19, 2026

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga

Aug 19, 2026

IONS Initiates Coverage On BMO Capital -- Price Target Announced at $60 - GuruFocus

Aug 19, 2026

BMO initiates Ionis Pharmaceuticals stock at Market Perform, PT $60 By Investing.com - Investing.com Canada

Aug 19, 2026

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm

Aug 19, 2026

Aug 18, 2026

IONS Looks 24.0% Overvalued on GF Value™ - GuruFocus

Aug 18, 2026

TimesSquare Capital Management LLC Takes $48.69 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 18, 2026

Grandfield & Dodd LLC Invests $2.94 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 18, 2026

Aug 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 17, 2026

Familial Amyloid Polyneuropathy Market - Future Market Insights

Aug 17, 2026

Ionis Pharma (IONS): FDA Catalysts, Accelerating Revenue And A Path To 2028 Cash-flow Breakeven - RTTNews

Aug 17, 2026

Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $94 - Moomoo

Aug 17, 2026

Ionis Pharmaceuticals (IONS) Stock Analysis: Exploring a 56% Potential Upside in Biotech Innovation - DirectorsTalk Interviews

Aug 17, 2026

Aug 16, 2026

Ionis Pharmaceuticals Inc (HAM:ISI) Stock Price, Trades & News - GuruFocus

Aug 16, 2026

Ionis Pharmaceuticals Trades at 10.9x Sales as Pipeline Optimism Clashes With Valuation Reality - finance.biggo.com

Aug 16, 2026

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales - Yahoo Finance

Aug 16, 2026

Empowered Funds LLC Increases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 16, 2026

ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks - TradingView

Aug 16, 2026

Aug 15, 2026

Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain? - Yahoo Finance

Aug 15, 2026

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - stocktwits.com

Aug 15, 2026

Aug 14, 2026

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool

Aug 14, 2026

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool

Aug 14, 2026

Aug 12, 2026